相似文献
1
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.
Haematologica. 2009 Jan;94(1):146-8. doi: 10.3324/haematol.13484. Epub 2008 Nov 10.
2
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
3
Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
Cancer J. 2005 Sep-Oct;11(5):425-31. doi: 10.1097/00130404-200509000-00011.
4
Bone marrow transplantation for Hodgkin's disease and lymphoma.
Annu Rev Med. 1993;44:255-63. doi: 10.1146/annurev.me.44.020193.001351.
5
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
6
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Ann Oncol. 2003;14 Suppl 1:i11-6. doi: 10.1093/annonc/mdg703.
7
Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
Med Pediatr Oncol. 1990;18(6):447-53. doi: 10.1002/mpo.2950180603.
8
9
Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives.
Haematologica. 2007 Jan;92(1):6-10. doi: 10.3324/haematol.11130.
10
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.
引用本文的文献
1
Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.
Stem Cell Rev Rep. 2025 Jun 18. doi: 10.1007/s12015-025-10912-w.
2
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
Bone Marrow Transplant. 2025 Jan;60(1):19-27. doi: 10.1038/s41409-024-02431-y. Epub 2024 Oct 7.
3
Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis.
Cells. 2023 Dec 18;12(24):2855. doi: 10.3390/cells12242855.
4
The role of transplantation in Hodgkin lymphoma.
Front Oncol. 2023 Jan 26;12:1054314. doi: 10.3389/fonc.2022.1054314. eCollection 2022.
5
Hodgkin's Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up.
Saudi J Med Med Sci. 2019 Sep-Dec;7(3):195-201. doi: 10.4103/sjmms.sjmms_96_19. Epub 2019 Aug 28.
6
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.
Blood Lymphat Cancer. 2017;7:37-52. doi: 10.2147/BLCTT.S105458. Epub 2017 May 9.
7
A Review of Autologous Stem Cell Transplantation in Lymphoma.
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1.
8
Hodgkin lymphoma, version 2.2015.
J Natl Compr Canc Netw. 2015 May;13(5):554-86. doi: 10.6004/jnccn.2015.0075.
本文引用的文献
1
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 2007 Jul 23.
2
3
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
Blood. 2006 Jan 1;107(1):52-9. doi: 10.1182/blood-2005-06-2252. Epub 2005 Sep 8.
4
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
J Clin Oncol. 2003 Jun 15;21(12):2320-5. doi: 10.1200/JCO.2003.11.103.
5
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
N Engl J Med. 1998 Nov 19;339(21):1506-14. doi: 10.1056/NEJM199811193392104.
6
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.
Blood. 1998 Sep 15;92(6):1933-40.
7
Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
Bone Marrow Transplant. 1991 Aug;8(2):99-103.
8
Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
J Clin Oncol. 1990 Jul;8(7):1173-86. doi: 10.1200/JCO.1990.8.7.1173.
Zotero 插件